DDInter7 DDInter1658
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Abemaciclib may lead to a major life threatening interaction when taken with Troleandomycin
Abemaciclib may lead to a major life threatening interaction when taken with Fingolimod